pharma · Non Small Cell Lung Cancer · Locally Advanced Solid Tumor · TNGX
Tango Therapeutics
Tango Therapeutics is a pharma organization headquartered in Boston, USA. It trades on NYSE under ticker TNGX. Primary therapeutic focus areas include Non Small Cell Lung Cancer, Locally Advanced Solid Tumor, MTAP-delete
Boston, USA HQ
2017 Founded
154 Employees
Public company Type
TNGX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Boston, USA
- Founded
- 2017
- Employees
- 154
- Programs
- 7
- Drugs
- 2
- Patents
- 9
TNG456
Phase 2 · small molecule · Non Small Cell Lung Cancer
TNG456 for Non Small Cell Lung Cancer is a Phase 2 program (small_molecule) at Tango Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code TNG456-C101
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Tango Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Non Small Cell Lung Cancer
- Status
- active
- Trials
- 1